A comment on the editorial Uso de maconha na adolescência e risco de esquizofrenia (Cannabis use in adolescence and risk of schizophrenia) by Carlini, Elisaldo Araujo et al.
Rev Bras Psiquiatr 2004;26(2):135-8
times;
4) Therefore, the statement suggesting that lifetime use can be a
‘naive’ one may be contested.
EA Carlini, José Carlos Galduróz, Ana Regina Noto e Solange A Nappo
CEBRID – Brazilian Information Center on Psychotropic Drugs
Who suffers the impact: some observa-
tions on health
Mr. Editor,
The editorial entitled ‘Who suffers the impact: considerations
about conflicts of interest’, published in September 2003, has
focused on the impact factors, the politics of publication and the
conflicts of interest. We would like to add some comments to that
article, especially regarding the study by De Meis et al., initially
presented in a lecture at the Institute of Advanced Studies of the
University of São Paulo -IEA/USP, and, several months afterwards,
fully published in the Brazilian Journal of Medical and Biological
Research.1 It is important to highlight that in this full version
appear the impacts of the current academic rules on the
researchers’ health. This reservation is not totally irrelevant as,
differently from conflict of interests, the mental health of this type
of worker is scarcely studied in our milieu. But, are researchers
workers? Do they suffer with the new configurations of the aca-
demic work? At which point the psychical aspects interfere in this
type of work? How can be measured the quality of work in
Science? Are there differences in the working relations and condi-
tions according to each area of knowledge? 
De Meis et al.’s study seems to indicate that at least the second
question should be affirmatively answered. Their findings, from
interviews with tenured researchers and post-graduate students
of the biochemical field, pointed to the existence of a burnout syn-
drome in that group. Twenty-one percent (21%) of the researched
people had sought at least one psychiatric consultation or psycho-
logical therapy. In their conclusions these authors state that the
growth of Brazilian science occurs at the cost of the huge emotio-
nal stress of the people  involved.
At which point this would interest the clinician? Which type of
attention our researchers - and especially post-graduate students
as they still do not have the status of a researcher - receive
regarding this situation? Are there data in Brazil about this issue?
After all, if science is essential for the country’s growth, what has
been done for its builders? Those are questions which aim to
enlarge the reflection proposed by Clarice Gorenstein. Its time to
start, in our milieu, a comprehensive debate on this issue, as well
as it is beginning to occur in the international literature, in which
it is possible to find data on anxiety and frustration among
tenured researchers and young researchers (UK, US), due to the
difficulties of working insertion or adaptation to the current
demands of scientific work.2-4 In this debate most of the material
is found on opinion articles or scientific papers which use qualita-
tive methods. Some authors highlight that this subject is hardly
dealt with in surveys. Anyway, it is possible to identify two recent
surveys: one in Norway,5 performed in 2001, in which there were
found mental disorders among 17.2% of scientific post-graduate
students (n=396), firstly graduated in medicine; and other
Canadian study,6 which assessed the stress among medical stu-
ties. No other medication used in this service had such satisfacto-
ry results on equivalent number of patients and treatment dura-
tion.
Further controlled studies with larger samples are needed to
verify the positive finding reported.
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A comment on the editorial “Uso de macon-
ha na adolescência e risco de esquizofrenia
(Cannabis use in adolescence and risk of
schizophrenia)
In this editorial the authors K Weiser, M Weiser e M Davidson
commented that: 
‘In the Brazilian population, a recent study by SENAD (National
Antidrug Agency) reported that 9% of adolescents (our emphasis)
have already used cannabis at least once in lifetime. This concept
(our emphasis), however, has been contested by recent longitudi -
nal studies ...This should warn us to the fact that the ‘naïve’ use
(authors’ quotes) of drugs ... ”
Due to the authors’ unintended confusion, we believe necessary
to provide some explanations:
1) The cited study was planned and developed by CEBRID
(Brazilian Information Center on Psychotropic Drugs) of UNIFESP/
EPM (Federal University of São Paulo/ Paulista Medical School);
SENAD has only sponsored the study; 
2) In our study, 6.9% of the interviewed population, aged 12 to 65
years, claimed having used cannabis at least once in lifetime;
therefore, figures were not of 9% of adolescents who stated such
use;
3) The concept of lifetime use cannot be contested by the ‘recent
longitudinal studies’, as they have different methodological
designs. In fact, lifetime use only reveals that the person has used
the drug at least once in his/her life, i.e., one, two, ten or thousand
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